Hana Ciferska

Prague, PR, Czech Republic

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment.

B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment.

Journal: Annals of the rheumatic diseases

Published: July 15, 2025

The Examination of a TPMT Gene Before Administration of Azathioprine in Rheumatology Practice and Identification of a Novel Variant p.W29R.

The Examination of a TPMT Gene Before Administration of Azathioprine in Rheumatology Practice and Identification of a Novel Variant p.W29R.

Journal: Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases

Published: December 06, 2021

VEXAS syndrome: a report of three cases.

VEXAS syndrome: a report of three cases.

Journal: Clinical and experimental rheumatology

Published: November 12, 2021

Does the renal expression of Toll-like receptors play a role in patients with IgA nephropathy?

Does the renal expression of Toll-like receptors play a role in patients with IgA nephropathy?

Journal: Journal of nephrology

Published: May 14, 2019

Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study.

Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study.

Journal: Annals of the rheumatic diseases

Published: May 05, 2017

Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results.

Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results.

Journal: Rheumatology (Oxford, England)

Published: December 13, 2016

Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study.

Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study.

Journal: Arthritis research & therapy

Published: August 26, 2015

A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.

A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.

Journal: Annals of the rheumatic diseases

Published: April 10, 2015

Complement system in SLE as a target for antibodies.

Complement system in SLE as a target for antibodies.

Journal: Current rheumatology reviews

Published: February 29, 2012

Showing 1-9 of 9

Last Updated: 09/26/2026